Edgewise Therapeutics Business Summary

Edgewise Therapeutics, Inc. (EWTX) is a clinical-stage biopharmaceutical company that operates on a research-and-development-heavy business model, currently generating no product revenue as it advances its late-stage pipeline toward commercialization. The company focuses on the discovery and development of orally bioavailable, small-molecule precision medicines for rare neuromuscular and cardiac disorders, primarily segmented into its skeletal muscle (dystrophinopathies) and cardiovascular (hypertrophic cardiomyopathy) programs. Its lead candidate, sevasemten (EDG-5506), is a first-in-class fast skeletal myosin inhibitor designed to prevent contraction-induced muscle damage in patients with Becker and Duchenne muscular dystrophy. Edgewise competes directly with Sarepta Therapeutics, Dyne Therapeutics, Avidity Biosciences, and Cytokinetics. Within this landscape, Edgewise distinguishes itself by offering a non-invasive, oral alternative to the complex gene therapies and injectable treatments pursued by its peers, targeting the underlying mechanical drivers of muscle deterioration rather than just protein replacement. The company was founded in 2017 by a high-pedigree team including Badreddin Edris, Ph.D., Alan Russell, Ph.D., and Peter A. Thompson, M.D. Leadership is currently headed by President and CEO Kevin Koch, Ph.D., a former Venture Partner at OrbiMed and co-founder of Array BioPharma with over 30 years of drug discovery experience at Biogen and Amgen. Alan Russell serves as the Chief Scientific Officer, bringing extensive expertise from his tenure as a VP at GlaxoSmithKline, while Michael Nofi recently joined as Chief Financial Officer from SpringWorks Therapeutics. The company is backed by a blue-chip roster of institutional investors and board members, including OrbiMed Advisors, Novo Holdings, Viking Global Investors, and RA Capital Management. Board Chair Peter Thompson, a Partner at OrbiMed, provides significant strategic oversight, leveraging his experience as a co-founder of multiple successful biotech ventures including Corvus Pharmaceuticals and Silverback Therapeutics.